Scripps Poway Eyecare & Optometry
San Diego, California, 92131, United States
NCT Number: NCT05498649
To subjectively evaluate Dailies Total1® contact lenses for astigmatism (DT1fA) performance compared to other common weekly/monthly contact lenses in symptomatic patients.
Looking for future studies?
Notify Me18 year–38 year
All sexes
Observational
San Diego, California, 92131, United States
This study is a single site, prospective, subject-masked, observational study of the subjective performance of DT1fA in symptomatic patients. Subjects will be assessed at a screening visit, and 2 follow-up visits. Clinical evaluations will include measurement of visual acuity, manifest refraction, and patient questionnaires.
Only the study team can determine whether someone qualifies for participation.
Subjects are eligible for the study if they meet the following criteria:
Note: Ocular criteria must be met in both eyes.
Inclusion criteria
Exclusion criteria
If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.
The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.
Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.
DT1fA contact lenses
Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)
A series of 8 questions that ask participants to rate eye discomfort, eye dryness, and blurry vision on a frequency scale (0 Never, 1 Rarely, 2 Sometimes, 3 Frequently, 4 Constantly) and an intensity scale (0 Never, 1 not intense to 5 Very Intense). Scores on individual questions are added together to determine a total score. Higher values indicate worse outcomes. The minimum score is 1 and the maximum score is 37.
Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)
Participants were asked to rate end of day discomfort intensity (0 Never, 1 not intense to 5 Very Intense). Higher values indicate worse outcomes.
Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)
Participants were asked to rate end of day dryness intensity (0 Never, 1 not intense to 5 Very Intense). Higher values indicate worse outcomes.
Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)
Participants were asked to rate noticeable change between clear to blurry or foggy vision (0 Never, 1 not intense to 5 Very Intense). Higher values indicate worse outcomes.
Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)
Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)
Time frame: Two to four weeks after fit with optimized prescription (Habitual lens) or two weeks after refit (Delefilcon A)
Keith Wan
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06775509
Astigmatism, Eye Diseases
Tarragona, Spain
View Trial DetailsNCT06784063
Astigmatism, Cataract
Bloomfield Hills, Michigan, United States
View Trial DetailsNCT06749496
Astigmatism, Eye Diseases
Jacksonville, Florida, United States
View Trial DetailsNCT06967129
Astigmatism, Eye Diseases
Mission Viejo, California, United States
View Trial Details